Vensana Capital closes $425M Fund III for breakthrough medical technology including neurotech
Summary
Vensana Capital announced closure of $425 million for their Fund III, dedicated to breakthrough medical technology companies with demonstrated clinical superiority. Neuromodulation and neural interfaces are explicitly in scope, as evidenced by Vensana leading Saluda Medical's $100M ECAP SCS financing. The $425M fund size makes Vensana one of the largest dedicated medtech venture funds, focusing on late-stage clinical de-risked companies approaching commercial scale.
Why it matters
A $425M medical device VC fund closing with explicit neuromodulation scope provides a large institutional capital source for Series C+ neurotech companies. Vensana's investment criteria — demonstrated clinical superiority over standard of care — matches the evidence profile of Saluda Medical (RCT superiority for Evoke), NeuroPace (long-term responder data), and future BCI companies that achieve pivotal trial success.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial